86. Skeletal Complications of Breast and Prostate Cancer Therapies

  1. Clifford J. Rosen MD
  1. Catherine Van Poznak and
  2. Pamela Taxel

Published Online: 19 JUL 2013

DOI: 10.1002/9781118453926.ch86

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition

How to Cite

Van Poznak, C. and Taxel, P. (2013) Skeletal Complications of Breast and Prostate Cancer Therapies, in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition (ed C. J. Rosen), John Wiley & Sons, Inc., Ames, USA. doi: 10.1002/9781118453926.ch86

Publication History

  1. Published Online: 19 JUL 2013

ISBN Information

Print ISBN: 9781118453889

Online ISBN: 9781118453926

SEARCH

Keywords:

  • breast cancer;
  • cancer therapies;
  • fracture;
  • metastatic bone disease;
  • osteoclast inhibition;
  • prostate cancer

Summary

This chapter reviews skeletal complications of cancer therapies with a focus on breast cancer and prostate cancer survivors. Patients with breast or prostate cancer likely exhibit a baseline risk of osteoporotic fractures due to advancing age and comorbid conditions; in addition, the management of their cancer may accelerate the risk for loss of bone mineral density (BMD) or fracture. Concerns for loss of BMD in metastatic disease are often supplanted by the frequent presence of bone metastases and the routine use of high potency osteoclast inhibitors to decrease the risk of skeletal-related events. Optimizing bone health practices through nutrition and/or supplements, weight-bearing exercises, and lifestyle modifications is essential. Clinical and radiographic assessment of fracture risk is a component of monitoring bone integrity. Pharmacologic interventions with bisphosphonates or denosumab are options to maintain BMD or reduce fracture in both the adjuvant and the metastatic setting.